Gold prices cool after rallying on Powell rate cut talk
WINSTON-SALEM, N.C. - ProKidney Corp. (NASDAQ:PROK), a late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced Tuesday the completion of its redomestication from the Cayman Islands to Delaware. The company, currently valued at $173 million, maintains a strong liquidity position with more cash than debt on its balance sheet.
The change in jurisdiction, which took effect July 1, was previously approved by shareholders at the company’s Annual General Meeting on May 29. As part of the transition, each Class A and Class B ordinary share automatically converted into corresponding Class A and Class B common stock of the Delaware-incorporated entity. The stock has faced significant headwinds, declining 76% over the past year, though InvestingPro analysis suggests the shares are currently trading below their Fair Value.
Trading of ProKidney’s common stock under the new structure will begin Wednesday, July 2, with the company maintaining its "PROK" ticker symbol on the Nasdaq Stock Market. The CUSIP number for the Class A common stock has changed to 74291D 104. With a current ratio of 10.96x, the company’s liquid assets substantially exceed its short-term obligations, though InvestingPro data reveals 12 additional key insights about the company’s financial position.
The company indicated in its press release that the redomestication is not expected to impact day-to-day business operations. Additional details about the process will be disclosed in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission. Despite reporting an EBITDA of -$173.73 million in the last twelve months, the company’s strong cash position provides runway for its development programs.
ProKidney is developing rilparencel, also known as REACT, an autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for preserving kidney function in diabetic patients at high risk of kidney failure. The treatment has received Regenerative Medicine Advanced Therapy designation from the FDA.
The information in this article is based on a company press release statement.
In other recent news, ProKidney Corp. has been downgraded by BofA Securities from Neutral to Underperform. The downgrade was accompanied by a significant reduction in the price target for ProKidney, from $3.00 to $1.00 per share. This change reflects a more conservative sales outlook for REACT, the company’s sole product candidate for treating diabetic chronic kidney disease. BofA now projects peak sales of $900 million for REACT, a decrease from its earlier estimate of $1.8 billion. The revision follows discussions with nephrology experts and adjustments in the competitive landscape. BofA expressed caution about ProKidney’s ability to advance the timeline for Phase 3 data, expected in the third quarter of 2027. The investment bank highlighted a financing overhang and limited near-term value-inflection catalysts, suggesting the risk/reward profile now skews to the downside. The revised price target is based on a discounted cash flow analysis reflecting the reduced sales forecast.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.